The Aesthetics Advisor

The era of GLP-1 weight loss drugs is no longer emerging—it’s already dominating modern medicine. In less than five years, medications like Ozempic, Wegovy, Mounjaro, and Zepbound have shifted obesity treatment from marginal success to clinically meaningful, double-digit weight loss backed by large-scale randomized trials . The numbers are not subtle. In pivotal studies, semaglutide (Wegovy) delivered ~15% average weight loss, while tirzepatide (Mounjaro/Zepbound) pushed results beyond 20%—approaching outcomes once only seen with bariatric surgery . At the same time, these drugs are showing cardiovascular risk reduction, improved glycemic control, and potential benefits across fatty liver disease, inflammation, and metabolic syndrome . Yet despite the hype, most comparisons online are superficial—and often misleading. These drugs are not interchangeable . They belong to different pharmacologic classes, target different hormone pathways, and produce meaningfully different outcomes in...

Quick Summary of Key Insights "Ozempic Face" is a result of rapid weight loss, not the drug itself. Up to 35-40% of weight lost can come from lean mass if not managed carefully. Gradual weight loss (1-2 pounds per week) is the gold standard for skin and muscle protection. Protein and resistance training are non-negotiable for preserving metabolic health. Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have revolutionized the treatment of obesity and type 2 diabetes. While these medications offer unprecedented weight loss efficacy, they also bring unique aesthetic and physiological challenges that require proactive management. Demystifying "Ozempic Face" The term "Ozempic Face" refers to the gauntness, sunken cheeks, and increased wrinkles that can appear during rapid weight loss. This occurs ...